in process …


Something bad happened. You should try to fix …


The action is completed.

Perry had minor success prior to her breakthrough. One

In recent years, there has been a major paradigm shift in the management of non-small cell lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver mutation if one is known or present. Translational research advances now allow such mutations to be inhibited by either receptor monoclonal antibodies (mAb) or small molecule tyrosine kinase inhibitors (TKI). Whilst empirical chemotherapy with a platinum-doublet remains the gold standard for advanced NSCLC without a known driver mu

Lee Perry, his wife of nearly 70 years, is living in an elder care facility, her once buoyant presence now lost to Perry himself, lucid as ever, has seen his physical frame become frail and stooped. Rather than slowing his schedule, he has accelerated his travels to plead with people to awaken to the danger. A trip to Washington includes a dinner with national security reporters and testimony on Capitol Hill. Back home in California, he’s at the Google campus to prod engineers to contemplate that their wo

BRAF mutations in NSCLC are uncommon and seen in less than 5% of cases (). As an part of the RAS/RAF/MEK/ERK or MAPK pathway, BRAF inhibition seemed logical, especially since TKIs were already available for melanoma (). However, only around half of those identified harbour the specific V600E mutation for which effective therapies exist (). Currently a phase II trial is looking at the combination of a BRAF and MEK inhibitor, dabrafenib and trametinib respectively, in stage IV NSCLC ( Identi

A successful omnichannel strategy should not only guarantee a retailer’s survival—no small matter in today’s environment—but also deliver a revolution in customers’ expectations and as an event and an experience

Related links


nsclc perry small mutation years